Organon & Co | OGN - Selling And Administration Expenses


Organon & Co reported $433M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Celltrion KRW 12.71B 237.27B Dec/2025
Cspc Pharmaceutical CNY 1.87B 95.62M Dec/2025
Deva Holding AS TRY 462.26M 48.18M Sep/2023
Dianthus Therapeutics USD 6.57M 1.62M Dec/2025
Divis Laboratories Ltd INR 3.4B 10M Jun/2025
Gilead Sciences USD 1.45B 326M Mar/2026
Glaxosmithkline GBP 3.56B 650.29M Dec/2025
Kangmei Pharma CNY 237.06M 37.35M Mar/2026
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Laboratorios Farma EUR 35.32M 2.75M Jun/2025
Malin Corporation EUR 1.1M 400K Dec/2024
Medical Developments International AUD 2.84M 4.19M Dec/2025
Merck USD 2.67B 180M Mar/2026
Neuren Pharmaceuticals AUD 3.74M 2.5M Dec/2025
Novartis USD 3.44B 132M Dec/2025
Organigram Holdings CAD 7.73M 1.13M Dec/2025
Organon & Co USD 433M 34M Dec/2025
Ovoca Bio EUR 632K 2.33M Jun/2025
Pharma Mar EUR 15.31M 2M Mar/2026
Qiagen NV USD 153.88M 10.77M Dec/2025
Sartorius EUR 221.3M 500K Mar/2026
Sino Biopharmaceutical CNY 7.54B 2.23B Jun/2025
Tilray USD 24.85M 1.7M Sep/2025
Zealand Pharma A/S 91.81M 99.04M Dec/2025